Table 2.
| Biomarker | N (%) | ||||
|---|---|---|---|---|---|
|
| |||||
| All participants N=1108 | History of anogenital dysplasia/ cancer N=72 | Partner of HPV related cancer case N=94 | Men 30 years and older with 2 or more lifetime oral sex partners N=942 | P-value~ | |
|
| |||||
| ORAL RINSE : Number tested | N=1105 | N=72 | N=94 | N=939 | |
| Any oncogenic HPV DNA | 81* (7.3) | 6 (8.3) | 6 (6.4) | 69 (7.4) | 0.89 |
| HPV16 DNA (by DEIA/LiPA or Cobas) | 20 (1.8) | 1 (1.4) | 1 (1.1) | 18 (1.9) | 0.81 |
| Any other oncogenic HPV DNA (by DEIA/LiPA or Cobas) | 67 (6.1) | 5 (6.9) | 5 (5.3) | 57 (6.1) | 0.91 |
| HPV 18 DNA (by DEIA/LiPA) | 7 (0.6) | 2 (2.8) | 0 | 5 (0.5) | 0.11 |
| HPV 31 DNA (by DEIA/LiPA) | 7 (0.6) | 1 (1.4) | 1 (1.1) | 5 (0.5) | 0.28 |
| HPV 33 DNA (by DEIA/LiPA) | 6 (0.5) | 2 (2.8) | 0 | 4 (0.4) | 0.08 |
| HPV 51 DNA (by DEIA/LiPA) | 15 (1.4) | 1 (1.4) | 1 (1.1) | 13 (1.4) | 0.97 |
| Any oncogenic HPV RNA (by Aptima)o | 20 (1.8) | 3 (4.2) | 0 | 17 (1.8) | 0.13 |
| Any oncogenic HPV DNA or RNA | 86 (7.8) | 7 (9.7) | 6 (6.4) | 73 (7.7) | 0.73 |
|
| |||||
| SERUM ANTIBODIES: Number tested | N=997 | N=63 | N=83 | N=851 | |
| Any oncogenic HPV E6 or E7# antibodies | 179* (22.9) | 12 (25.5) | 11 (18.3) | 156 (23.2) | 0.63 |
| HPV16 E6 or E7 | 77 (7.7) | 7 (11.1) | 6 (7.2) | 64 (7.5) | 0.58 |
| Other oncogenic HPV E6 or E7# | 119 (15.7) | 7 (15.6) | 7 (12.1) | 105 (16.0) | 0.73 |
|
| |||||
| HPV16 | |||||
| HPV16 E6 | 22 (2.2) | 2 (3.2) | 2 (2.4) | 18 (2.1) | 0.85 |
| HPV16 E7 | 57 (5.7) | 6 (9.5) | 4 (4.8) | 47 (5.5) | 0.39 |
| HPV16: ≥3 of: E1, E2, E6, E7 | 2 (0.2) | 0 | 0 | 2 (0.24) | 0.99 |
|
| |||||
| Other oncogenic HPV types | |||||
| Other oncogenic HPV E6 | 70 (7.0) | 2 (3.2) | 6 (7.2) | 62 (7.3) | 0.47 |
| Other oncogenic HPV E7# | 59 (8.1) | 5 (11.4) | 1 (1.8) | 53 (8.5) | 0.15 |
|
| |||||
| ELIGIBLE FOR AT-RISK COHORT | |||||
| Any oncogenic HPV: oral HPV DNA/RNA or serum E6 or E7 antibodies | 248 (22.4) | 18 (25.0) | 15 (16.0) | 215 (22.8) | 0.27 |
Oncogenic HPV strains were defined to include types 16,18,31,33,35,45,52, 58 (both serum and oral rinse), and types 39,51,56,59,66, 68 (tested in oral rinse only)
Eligibility group categories were made mutually exclusive for this table, using the following hierarchy for participants reporting multiple categories: History of anogenital dysplasia/cancer, partner of HPV related cancer case, men ≥30 years with ≥ 2 lifetime oral sex partners
This row excludes 3 samples with invalid results, thereby bringing total rinse samples with Aptima testing to N=1102
Excludes a subset of non-16 oncogenic HPV E7 results from one batch of test results, which were set to missing due to higher-than-expected prevalence.
P-value tested with chi square test for categorical variables. When any biomarker categories had <10 participants positive, Fishers exact tests used.
These include people that can be positive for either or both of the two rows listed below; as they are not counted twice here the total does not equal the sum of rows below